Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers - Trial NCT04611932
Access comprehensive clinical trial information for NCT04611932 through Pure Global AI's free database. This Phase 1 trial is sponsored by Chong Kun Dang Pharmaceutical and is currently Not yet recruiting. The study focuses on Cardiovascular Disease. Target enrollment is 51 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Chong Kun Dang Pharmaceutical
Timeline & Enrollment
Phase 1
Nov 11, 2020
Apr 27, 2021
Primary Outcome
AUCt of CKD-330, D090, CKD-333,Cmax of CKD-330, D090, CKD-333
Summary
This study is a randomized, open-label, single dose, 3-period partial replicated crossover
 study to evaluate the pharmacokinetic profiles and safety of CKD-333 low dose in healthy
 volunteers under fasting conditions.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04611932
Non-Device Trial